| Budget Amount *help |
¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1996: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1995: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1994: ¥700,000 (Direct Cost: ¥700,000)
|
|---|
| Research Abstract |
We established cisplatin resistant ovarian cancer cell line (NOS2CR), Which showed about 50-fold resistant to cisplatin compared with parental cell line (NOS2). By SDS-PAGE,2 bands were clearly augmented, 1 was weakened, and 1 was disappeared in NOS2CR.However, it was difficult to identify proteins corresponding to these bands due to contamination of other bands. Detoxification by glutathione was one of the mechanisms for cisplatin resistance. Thus, glutathione binding proteins were eluted by glutathion column and were electrophoresed. Several bands were appeared and disappeared in NOS2CR.We analyzed amino-acid sequence, but the most clear band was glutathione-S-transferase, which is a key enzyme of glutathione cycle. Other bands could not be analyzed in an ordinary way, suggesting that proteins were modified. On the other hand, carboplatin and aqupla are also available for cancer treatment. We further established carboplatin resistant cell line (NOS2CBR) and examined the sensitivity against platinum and other anticancer drugs, which were used for cancer treatment. These cell lines showed cross resistance to platinum anticancer drugs, suggesting that the same mechanisms were acquired in both resistant cell lines.
|
